Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis
Completed · Not applicable
Conditions studied: Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
In brief
The goal in these studies will be to assess the relative levels of the Stat4 alpha and Stat4 beta isoforms in PBMCs from patients with Crohn's Disease, ulcerative colitis, celiac disease or from control patients. We hypothesize that the beta to alpha ratio will be higher in patients with active disease and that there will be a correlation between the ratio and the severity of disease.
Key facts
- Study ID
- NCT00586599
- Run by
- Indiana University
- People needed
- 51
- Starts
- 2007-08-01
- Expected to finish
- 2014-07-01
- Last updated by the study team
- 2015-04-03
Who can join
Age: 7 and older, up to 17. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Children with a new diagnosis of Crohn's Disease and whose physician has not yet initiated corticosteroid treatment (10 Subjects):
- Clinical diagnosis within the previous 21 days
- Above age 7 and younger than age 18
- Signed informed consent statement and assent statement.
- Children with a new diagnosis of Ulcerative Colitis and whose physician has not yet initiated corticosteroid treatment (10 Subjects):
- Clinical diagnosis within the previous 21 days
- Above age 7 and younger than age 18
- Signed informed consent statement and assent statement.
- Children with Crohn's Disease whose physician has initiated Infliximab treatment for the first time (10 Subjects):
- Clinical diagnosis of Crohn's Disease
- Above age 7 and younger that age 18
- Signed informed consent statement and assent statement.
- Children with Ulcerative Colitis whose physician has initiated Infliximab treatment for the first time (10 Subjects):
- Clinical diagnosis of Ulcerative Colitis
- Above age 7 and younger than age 18
- Signed informed consent statement and assent statement.
- Healthy Controls (10 Subjects):
- Above age 7 and younger than age 18
- otherwise healthy, with no intercurrent illness as determined by a member of the study team using the eligibility checklist
- controls will be gender and age (± 2 years) matched to the patient groups described above
- Signed informed consent statement and assent statement
You may not qualify if…
- unwilling to give consent for this study.
- child with prior prescription and administration of Infliximab
Where it is running
- Indiana University-Riley Hospital — Indianapolis, Indiana, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.